PreveCeutical Announces Date for Annual General and Special Meeting

Rhea-AI Summary

PreveCeutical Medical (OTCQB: PRVCF) has scheduled its annual general and special meeting for August 15, 2025. Shareholders will vote on director elections, auditor appointments, and notably, a plan to distribute up to 12 million common shares of BioGene Therapeutics to PreveCeutical shareholders.

The arrangement will result in shareholders owning stakes in two separate companies: BioGene, focusing on Dual Gene Therapy program development, and PreveCeutical, continuing its focus on preventive and curative therapies using organic products. This strategic separation aims to expand both companies' shareholder bases and improve access to capital for research and development.

Positive

• Strategic separation will allow for more focused investment opportunities in specific business segments
• Potential for improved access to capital for both companies' research and development
• Shareholders will maintain ownership in both companies post-distribution

Negative

• None.

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has scheduled its annual general and special meeting for August 15, 2025, at which the shareholders (the "PreveCeutical Shareholders") of the Company will be asked to approve:

1. the election of Stephen Van Deventer, Makarand Jawadekar, Linnéa Olofsson, Kathleen Rokita and C. Evan Ballantyne as directors of the Company;

2. the ratification of the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the auditors of PreveCeutical for the financial year ending December 31, 2024, and 2025;

3. a plan of arrangement under the provisions of Division 5 of Part 9 of the Business Corporations Act (British Columbia), pursuant to which the Company will distribute up to 12,000,000 common shares of BioGene Therapeutics Inc. ("BioGene") to the PreveCeutical Shareholders; (the "Arrangement and Distribution") and

4. the adoption of the PreveCeutical's Omnibus Equity Incentive Plan.

Once the Arrangement and Distribution is complete, the PreveCeutical Shareholders will own shares in two companies: BioGene, which will focus on the development of the Dual Gene Therapy program, and PreveCeutical, which will continue to focus on developing innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical believes that the Arrangement and Distribution is in the best interests of PreveCeutical and the PreveCeutical Shareholders for numerous reasons, including that separating PreveCeutical and BioGene will expand both PreveCeutical's and BioGene's potential shareholder base and access to capital for research, development and clinical trials by allowing investors that want specific ownership in the particular business of BioGene the opportunity to invest directly in BioGene rather than through PreveCeutical.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.

On behalf of the Board of Directors of PreveCeutical

Stephen Van Deventer, Chairman and Chief Executive Officer

For further information, please contact:

Stephen Van Deventer: +1 604 306 9669 Or 
Investor Relations ir@preveceutical.com

Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256761

FAQ

When is PreveCeutical's (PRVCF) annual general meeting scheduled for 2025?

PreveCeutical's annual general and special meeting is scheduled for August 15, 2025.

How many BioGene Therapeutics shares will be distributed to PreveCeutical shareholders?

PreveCeutical plans to distribute up to 12 million common shares of BioGene Therapeutics to its shareholders.

What will be the focus areas of PreveCeutical and BioGene after the separation?

BioGene will focus on the Dual Gene Therapy program development, while PreveCeutical will continue developing preventive and curative therapies using organic and nature identical products.

Who are the proposed directors for PreveCeutical's board in 2025?

The proposed directors are Stephen Van Deventer, Makarand Jawadekar, Linnéa Olofsson, Kathleen Rokita and C. Evan Ballantyne.

What is the purpose of PreveCeutical's separation from BioGene Therapeutics?

The separation aims to expand both companies' shareholder bases and improve access to capital by allowing investors to invest directly in their preferred business segment.